J&J secures FDA approval for biweekly dosing of Tecvayli to treat RRMM
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Tecvayli (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks.